Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Consolidated Net Income: 2017-2024

Historic Consolidated Net Income for Kiniksa Pharmaceuticals International (KNSA) over the last 8 years, with Dec 2024 value amounting to -$43.2 million.

  • Kiniksa Pharmaceuticals International's Consolidated Net Income rose 245.24% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.9 million, marking a year-over-year increase of 142.99%. This contributed to the annual value of -$43.2 million for FY2024, which is 28.48% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Consolidated Net Income stood at -$43.2 million for FY2024, which was up 28.48% from -$60.4 million recorded in FY2023.
  • Kiniksa Pharmaceuticals International's Consolidated Net Income's 5-year high stood at $267.4 million during FY2022, with a 5-year trough of -$167.1 million in FY2020.
  • Moreover, its 3-year median value for Consolidated Net Income was -$43.2 million (2024), whereas its average is $54.6 million.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Consolidated Net Income skyrocketed by 261.42% in 2022, and later plummeted by 122.58% in 2023.
  • Kiniksa Pharmaceuticals International's Consolidated Net Income (Yearly) stood at -$167.1 million in 2020, then increased by 0.88% to -$165.7 million in 2021, then soared by 261.42% to $267.4 million in 2022, then plummeted by 122.58% to -$60.4 million in 2023, then climbed by 28.48% to -$43.2 million in 2024.